Evaluation of oral budesonide in the treatment of active distal
ulcerative colitis

Kolkman, Jeroen J.; Möllmann, A.C.; Peña, Amado Salvador; Greinwald, Roland; Tauschel, Horst-Dietmar; Hochhaus, Günther

doi:10.1358/dot.2004.40.7.850477

Cited by 21 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24,25 Special formulations of budesonide, however, may reach the distal colon. 26 In line with this, colitis in patient 2 remained in remission under alternating dosages of 3 mg budesonide. It is possible that cholestasis might be perpetuated due to extrahepatic inflammation as the primary insult.…”

Section: Figurementioning

confidence: 53%

Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2

et al. 2015

View full text Add to dashboard Cite

Mutations in the gene encoding the canalicular bile salt export pump (BSEP) can result in progressive familial intrahepatic cholestasis type 2 (PFIC-2). Treatment options are limited, and PFIC-2 often necessitates liver transplantation. We report on a young woman and a boy who clinically presented with PFIC-2 phenotypes and dramatically improved with steroid treatment. Gene sequencing of ABCB11 encoding for BSEP revealed 2 relevant mutations in both patients. The young woman was compound heterozygous for p.T919del and p.R1235X. At the age of 5 years, partial biliary diversion was performed and rescued liver function but left serum bile salt levels elevated. At age 23 she developed systemic lupus erythematosus. Unexpectedly, steroid therapy normalized serum bile salt levels, with a strong correlation with the steroid dose. She is currently in clinical remission. The boy was compound heterozygous for the ABCB11 mutations c.150+3A>C and p.R832C and presented with intractable pruritus. When he developed colitis, he was treated with steroids. The pruritus completely disappeared and relapsed when steroids were withdrawn. To date, with low-dose budesonide, the boy has been symptom-free for >3 years. In conclusion, the clinical courses suggest that patients with BSEP deficiency and residual BSEP activity may benefit from steroid-based therapy, which represents a new treatment option.

show abstract

Section: Figurementioning

confidence: 53%

Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The remission rate seen in the 12-mg induction group is similar to the remission rate observed with oral corticosteroids, 9,10,13-15 even though the colon is affected. Oral budesonide has often been limited to therapy of the ileum and ascending colon 11,12,15,22 in clinical trials, which can introduce bias in trying to interpret the remission rates in real-life scenarios. A recent study performed in patients with ulcerative colitis given oral pHmodified budesonide detected significant levels in mucosal biopsies, and a better response rate after 9-mg once-daily dosing (71%) in the distal colon after 8 weeks than after 3 mg 3 times/day (38%), 21 further illustrating that pH-modified oral budesonide can be used in CD patients even if the colon is significantly involved.…”

Section: Discussionmentioning

confidence: 99%

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohnʼs disease: A randomized placebo-controlled trial

Levine

Kori

Dinari

et al. 2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Budesonide allowed ending the steroid treatment. The third study, in patients with distal active UC, oral budesonide (Budenofalk ® ) showed encouraging clinical results (42). This study, particularly designed to study the pharmacokinetics and pharmacodynamics of Budenofalk ® , found significant levels of budesonide in the distal colon and rectum.…”

Section: Oral Budesonidementioning

confidence: 93%

“…However, no evidence for the efficacy of oral budesonide in UC is yet available. Budenofalk ® , which dissolves at pH > 6.4 and delivers budesonide in acceptable quantities to the distal colon and rectum in UC patients, may be useful for the treatment of UC patients (42). Since Entocort ® can reach the transverse and descending colon (43) a comparative trial, as some authors have already suggested (6), between the two oral formulations of budesonide would be of interest.…”

Section: Future Perspectivesmentioning

confidence: 99%

Budesonide for ulcerative colitis

Marín-Jiménez

Peña

2006

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

In this review, we examined studies published on oral and topical formulations of budesonide (Entocort ® and Budenofalk ® , in Spain: Entocord ® and Intestifalk ® ) for the treatment of ulcerative colitis. This glycocorticosteroid has a potent local action and an important first-pass liver metabolism. It has proven successful over the last years as a controlled-release formulation. It obtained results similar to prednisolone, without the latter's significant suppression of plasma cortisol. Many publications exist on the effects of oral budesonide for the treatment of Crohn's disease (CD). These have led to the registration of this drug for the treatment of CD. Studies on oral formulations of budesonide for the treatment of ulcerative colitis (UC) are scarce. After reviewing published evidence, we suggest the conduction of controlled trials for the treatment of UC to obtain evidence-based efficacy and safety results in order to benefit patients with this form of inflammatory bowel disease (IBD).

show abstract

Evaluation of oral budesonide in the treatment of active distal ulcerative colitis

Cited by 21 publications

References 0 publications

Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2

Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohnʼs disease: A randomized placebo-controlled trial

Budesonide for ulcerative colitis

Contact Info

Product

Resources

About